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Abstract
Background: Dietary fish oil, rich in n-3 fatty acids (n-3 FAs), e.g. docosahexaenoic acid (DHA) and eicosapentaenoic acid
(EPA), regulate inflammatory reactions by various mechanisms, e.g. gene activation. However, the effects of long-term
treatment with DHA and EPA in humans, using genome wide techniques, are poorly described. Hence, our aim was to
determine the effects of 6 mo of dietary supplementation with an n-3 FA preparation rich in DHA on global gene expression
in peripheral blood mononuclear cells.
Methods and Findings: In the present study, blood samples were obtained from a subgroup of 16 patients originating from
the randomized double-blind, placebo-controlled OmegAD study, where 174 Alzheimer disease (AD) patients received daily
either 1.7 g of DHA and 0.6 g EPA or placebo for 6 months. In blood samples obtained from 11 patients receiving n-3 FA
and five placebo, expressions of approximately 8000 genes were assessed by gene array. Significant changes were
confirmed by real-time PCR. At 6 months, the n-3 FAs group displayed significant rises of DHA and EPA plasma
concentrations, as well as up- and down-regulation of nine and ten genes, respectively, was noticed. Many of these genes
are involved in inflammation regulation and neurodegeneration, e.g. CD63, MAN2A1, CASP4, LOC399491, NAIP, and SORL1
and in ubiqutination processes, e.g. ANAPC5 and UBE2V1. Down-regulations of ANAPC5 and RHOB correlated to increases of
plasma DHA and EPA levels.
Conclusions: We suggest that 6 months of dietary n-3 FA supplementation affected expression of genes that might
influence inflammatory processes and could be of significance for AD.
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Introduction
Omega-3 fatty acids (n-3 FAs), e.g. eicosapentaenoic acid (EPA;
20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3), present in
marine oils, modulate inflammatory reactions and ameliorate
symptoms of several autoimmune and other inflammatory
disorders [1], [2]. In addition, EPA and DHA administration
reduces cardiovascular morbidity and mortality, e.g. from
ventricular arrhythmias [3]. Recently, high fish intake or dietary
supplementation with n-3 fatty acids has been linked to reductions
in the risk of developing Alzheimer’s disease (AD) [4], [5], [6] and
to delayed cognitive decline in patients with very mild AD [7].
N-3 FA are considered to exert the anti-inflammatory effects on
several cellular levels, including surface receptor modulation, ion
pumps, G-proteins, binding to transcription factors (e.g. nuclear
transcription factor kB /NFkB/ and other signalling systems), as
well as on gene activation [8], [9], [10]. Previous investigations on
effects of DHA and/or EPA on gene expressions in animal studies
and in vitro models have shown changes in a variety of genes, some
of which are believed to be involved in inflammation and chronic
neurodegenerative disorder. These gene expression studies have
mostly been conducted after a short time exposure and on small
sets of genes [11], [12], [13], [14], [15], [16], [17], [18]. However,
a microarray study on the cerebral cortex of neonate baboon after
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approximately 1000 probesets/genes (but none more than 2-fold)
[19]. In murine studies, 3 weeks of dietary supplementation of fish
oil changed five genes more than 2-fold, and DHA enriched fish
oil for approximately 2 months identified 329 and 356 dietary
regulated transcripts from liver and hippocampus, respectively
[20], [21]. There were no published studies of effects of long-term
treatment with EPA and DHA in humans, using genome wide
techniques, until recently [22].
Here, we present results of a clinical trial, the OmegAD study
[7], where a product rich in DHA was given to patients with mild
to moderate AD. The goal of the OmegAD study was, inter alia, to
see if this n-3 preparation would reduce the cognitive deteriora-
tion. In the present study of the OmegAD trial, we used global
transcriptome profiling to detect new genes responding to DHA-
rich n-3 supplementation in isolated peripheral blood mononu-
clear cells (PBMCs). Preliminary results from this study has been
presented previously [23].
Materials and Methods
Subjects
This per-protocol study, included finally 16 patients (see
Supplementary Material S1) for details of in- and exclusions),
Figure 1. They were among the first to be randomized in the
OmegAD study, described in detail in [7]. In summary, the double
blind, placebo controlled OmegAD study included 204 patients
(7369 y, 52% women) with mild to moderate AD. Patients were
randomized to 6 months of nutritional supplementation with a
marine n-3 fish oil rich in DHA or to placebo. Patients were
treated daily with either 1.7 g DHA plus 0.6 g EPA (EPAX
1050TG; Pronova Biocare A/S, Lysaker, Norway) or with
isocaloric placebo oil (1 g corn oil, including 0.6 g linoleic acid)
for 6 months. EPAX 1050TG is a 60% n-3 fatty acid concentrate
in triacylglycerol form, produced according to good manufactur-
ing practices. Four milligrams of vitamin E (tocopherol) was added
to each EPAX 1050TG and placebo capsule. A total of 174
patients completed the OmegAD study. Plasma fatty acid profiles,
cognition and behavioural data have been published [7], [24]. A
pre-trial power calculation in the whole study, estimated that 200
patients have to be included with a statistical significance level of
0.05 and 80% power to accomplish differences in the measure-
ment of the cognitive function. The estimation of numbers of
enrolled patients in our gene expression subgroup by power
calculation has not been applicable, due to insufficient knowledge
as to variables included in the power calculation for the thousands
of genes measured by the microarray technique. Here, we present
data on 11 (54–82 y; median 71, and 5 woman) patients, who
received the n-3 FAs preparation, and 5 patients (56–80 y; median
66, and 2 woman), receiving the placebo oil, for 6 months.
No changes in peripheral blood neutrophil, monocyte, and
lymphocyte cell counts were recorded after 6 months of n-3 FAs
treatment. In this study group, no specific advice on food intake
was given, since included patients suffered from AD.
Blood sampling
EDTA anticoagulated venous blood was obtained prior to or
after 6 months of n-3 FA treatment. PBMCs were isolated by
means of a Lymphoprep (Nycomed Pharma, Oslo, Norway)
gradient centrifugation. The cell preparations obtained before and
after treatment with n-3 FAs, contained on average 14%
monocytes and 86% lymphocytes on both occasions. Correspond-
ing figures for the placebo group were 15% and 85%, respectively.
The cell viability in both groups was on average 96%, as assessed
by trypan blue staining.
RNA extraction and microarray hybridization
Total RNA was isolated from PBMCs according to protocols
given in Supplementary Material S1. From non-degraded high-
quality total RNA we prepared biotinylated complementary RNA
that served as template for hybridization to Human Genome
Focus Arrays (Affymetrix, Inc., Santa Clara, CA) containing 8747
probesets, corresponding to approximately 8000 genes (see
Supplementary Material S1).
Microarray data analysis
Information about calculation of signal intensities for each
microarray and quality control in Microarray Analysis Suite
(MAS) 5.0 (Affymetrix) are given in Supplementary Material S1.
Genes were categorized using the Gene Ontology (GO) database.
We used the software Significance Analysis of Microarrays
(SAM) [25] to identify changes in gene expression induced by n-3
FA treatment. Details of this procedure are given in Supplemen-
tary Material S1). In addition, we used SAM for sample size
calculation. Our dataset had limited power to detect differentially
expressed genes. However, the purpose of the study was not to
characterize the complete response of gene expression to the
intervention, but to detect a few responding genes.
Verification of microarray with real time PCR
We selected genes that were interesting biological candidates for
PCR confirmation, with the restriction that this selection should
not be biased and only represent those with the largest fold
change. RNA was reversed transcribed into cDNA, using an
iScript cDNA synthesizing kit. Real time-(RT)- PCR was
performed in an iCycler IQ (Bio-Rad Laboratories Inc., Hercules,
CA). The results were normalized to low density lipoprotein
receptor-related protein 10 (LRP10), whose mRNA levels were
unaffected by n-3 FA and placebo treatment. Details are given in
Supplementary Material S1.
Plasma fatty acid analyses
Plasma fatty acids (FAs) were analyzed by gas chromatography
(Thermo TR-Fame column (30 m60.32 mm ID60.25 mm film;
Thermo Electron Corp, Waltham, MA) and are given as relative
abundance of individual fatty acids [26] in each participating
individual. Data for all 174 patients in the OmegAD study have
been given previously [7]. Changes of the EPA and DHA plasma
concentrations are given as the difference of percentage units.
Statistical analyses
Paired two sided Students’ t-tests were used to analyze changes
in plasma FAs- and gene expression data. For microarray data, the
results for the n-3 FA group were adjusted for multiple
comparisons using SAM (see above). A two-sided independent
Students’ t-test was used to compare fold change between the n-3
FA and placebo groups. Paired one-sided Students’ t-tests were
used in confirmatory analysis of individual mRNA measurements
by RT-PCR. Values are presented as mean6SD. For correlation
analyses, Pearson correlation tests were applied. P values,0.05
were considered significant.
Dietary DHA and Gene Expression
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Plasma fatty acids
At study entry, plasma concentrations of EPA and DHA did not
differ significantly between the two groups (Figure 2). In the n-3
FAs group plasma values for DHA as well as for EPA were
significantly higher at 6 months compared with pre-trial values
(p=0.00006 and p=0.00004 respectively). The placebo group
displayed no significant alterations of DHA and EPA in plasma
compared with pre-trial values (Figure 2). The mean rise of DHA
levels was slightly larger than that of EPA in the n-3 FA group
(+3.6 percentage units and +3.14 percentage units, respectively).
Nonetheless, here, and as in our previous reports [7,24], EPA
values were enhanced more than expected from the ratio of orally
supplemented EPA to DHA, being 0.35:1.
Gene expression by microarray
Next, we assessed which genes, out of the 8000 on the
microarrays that showed a significant change in expression in
PBMCs following n-3 FA supplementation. All microarrays
fulfilled the employed quality criteria (see Supplementary Material
S1 for details). On the microarrays 4,075 probesets gave signals
that, according to the criteria in MAS 5.0, showed that the
corresponding mRNA was expressed in PBMCs on .15 of 22
arrays in the intervention group. Such genes were scored as
present in PBMCs and were further analyzed in SAM. According
to SAM analysis the expression of 19 genes were up- or down-
regulated in PBMCs by 6 month treatment with n-3 FA with a
false discovery rate of 10%.
Gene changes in the n-3 FA group
Table 1 presents results for significantly up-regulated genes in
PBMCs, after n-3 FAs supplementation for 6 months. The nine
up-regulated genes in the n-3 group are presented below, in falling
order of magnitude, and with comments on possible functions
(partly provided by Ref Seq at: http://www.ncbi.nlm.nih.gov/
RefSeq/).
MS4A3 (also known as CD20L and HTM4) encodes for a
member of the membrane-spanning 4A gene family. The
corresponding protein likely plays a role in signal transduction
and may function as a subunit associated with receptor complexes.
NAIP (also known as BIRC1) codes for a protein belonging to the
NLR family of apoptosis inhibitory proteins (AIP). It is thought
that this gene is a modifier of spinal muscular atrophy caused by
mutations in a neighbouring SMN1 gene. A low level of NAIP
protein has been found in AD brains. Further, it has been
suggested that a rise of the NAIP protein level protects AD patients
against the development of tangle pathology and cognitive decline
[27]. Thus, changes in this gene might be of significance for the
population of AD patients studied here.
DRG1 (also known as NEDD3, PROXY1, and NDRG1) encodes
for the developmentally regulated GTP binding protein-1. This
gene is a member of the N-myc down-regulated gene family,
which belongs to the alpha/beta hydrolase superfamily. The
encoded protein is cytoplasmic, involved in stress and hormone
responses, cell growth, and differentiation. It is necessary for p53-
mediated caspase activation and apoptosis. Mutation in this gene
has been reported to be causative for a hereditary variant of
Charcot-Marie-Tooth disease (type Lom), and is, thus, linked to a
degenerative nerve disorder.
The CD63 (also known as LAMP-3, OMA81H, and TSPAN30,
granulophysin) gene encodes for the CD63 antigen (also known as
melanoma-1 antigen) found e.g. in tissue macrophages. This cell-
surface protein belongs to the family of tetraspanin proteins
involved in cell adhesion and cell migration as well as neutrophil
granule mobilization [28]. Thus, it is clearly involved in regulation
of inflammation.
Figure 1. CONSORT flowchart. Study design at baseline and after n-3 FA or placebo supplementation to AD patients for 6 months.
AD=Alzheimer’s disease, n-3 FA=Omega-3 fatty acid treatment, Placebo=Placebo treatment.
doi:10.1371/journal.pone.0035425.g001
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dehydrogenase-1 (also known as DHRS8), modulates the intracel-
lular glucocortocoid levels and takes part in the steroid and lipid
biosynthetic processes. Again, this protein is involved in regulation
of inflammation.
RAB27A (also known as RAM, RAS-associated protein RAB27A).
The protein encoded by this gene belongs to the small GTPase
superfamily, Rab family. The protein is membrane-bound and
may be involved in protein transport and small GTPase mediated
signal transduction. Mutations in this gene are associated with
Griscelli syndrome type 2, an X-linked lymphoproliferative
syndrome associated with hemophagocytic syndromes [29],
indicating that this protein is involved in regulation of inflamma-
tion.
CASP4 (also known as ICE (rel) II, ICEREL-II, and ICH-2) codes
for caspase-4, an apoptosis-related cysteine protease, classified as
one of the inflammatory caspases. It participates in the LPS
induced TLR4-signaling pathway, acting as an essential protein in
the NF-kB activation of cytokine and chemokine production.
Hence, it is an important part of the innate immunity system [30].
Moreover, caspase-4 is considered as a key caspase in apoptotic
signalling in AD [31].
SUPT4H1 (also known as Suppressor of Ty4 homolog 1). The
protein from this gene has transcription factor activity and is
involved in RNA synthesis.
The ubiquitin-conjugating E2 enzyme variant-1 protein (en-
coded by the gene UBE2V1, also known as CROC1 and UEV1A)i s
located in the cell nucleus and can cause transcriptional activation
of the human FOS proto-oncogene. This protein belongs to the
ubiquitin-conjugating enzyme family but has no ligase activity on
its own but is one of the enzymes involved in the ubiquitination of
proteins.
Figure 2. Plasma values for docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) at baseline and after 6 months. Individual
values are flanked by mean and SD values. Significant increases of DHA and EPA were noted in the n-3 fatty acids (n-3 FAs) group after 6 months, but
not in the placebo group.
doi:10.1371/journal.pone.0035425.g002
Table 1. Genes up-regulated by a DHA rich n-3 fatty acid or placebo supplementation.
n-3 FA group
1 Placebo group
Locus Link Genes Fold change Fold change
MS4A3 Membrane-spanning-4 domains subfamily A 1.7260.83 0.0037 1.6561.12
NAIP NLR family, apoptosis inhibitory protein 1.3760.35 0.0028 1.1660.11
DRG1 Developmentally regulated GTP binding protein 1 1.2060.19 0.0033 1.146 0.11
2
CD63 CD63 molecule 1.2060.18 0.0019 0.9960.11
3
HSD17B11 Hydroxysteroid (17-beta) dehydrogenase 11 1.1960.15 0.0006 1.2760.55
RAB27A Member RAS oncogen family 1.1860.16 0.0024 1.0860.18
CASP4 Apoptosis-related cysteine peptidase 1.1760.14 0.0026 0.9960.20
4
SUPT4H1 Suppressor of Ty 4 homolog 1 1.1560.11 0.0008 1.0260.12
4
UBE2V1 Ubiqutin-conjugating enzyme E2 variant1 1.1360.10 0.0012 1.0660.22
All values are means6SD.
1All genes were significantly up-regulated by the n-3 FAs treatment according to SAM based on 2000 permutations and a false discovery rate of 10%, see microarray
data analysis for details.
2We analyzed by t-test if genes regulated by n-3 FAs supplementation were also up- or down-regulated in the placebo group. The change for DRG1 was significant
(p=0.04).
3Significant and
4close to significance (p=0.05–0.06) difference in fold change between the n-3 FAs and placebo group.
doi:10.1371/journal.pone.0035425.t001
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10 genes after 6 months of n-3 FAs treatment. They were, in
falling order of magnitude, in the n-3 group as follows.
RHOB (also known as ARH6) is a Ras homolog gene family
member B gene that encodes for a Rho-related GTP-binding
protein with GTPase activity, RhoB precursor protein. It is
involved in cell differentiation and cell adhesion. In different cell
models, RhoB can activate NF-kB signalling by modification of
the RelA/p65 transactivation domain [32], implying a role in
inflammation. Further, small GTPase RhoB has a critical role in
vascular development.
Valosin containing protein (VCP, also known as p97)i sa
structural endoplasmatic reticulum protein associated with clathrin
and heat shock protein Hsc70. It belongs to the family of putative
ATP-binding proteins involved in vesicle transport and fusion and
ubiqutin-dependent protein degradation. Polymorphism in this
gene may be linked to late onset AD [33].
LOC399491 encodes for a hypothetical protein, possibly a
membrane protein and a protein in the neuropeptide signalling
pathway. No pathology has so far been associated with this gene.
The zinc finger protein 24 gene (ZNF24, also known as ZNF191
and KOX17) is related to ZNF191, which probably is associated
with some hereditary diseases and cancers. ZNF24 may function as
a transcription factor.
SORL1 (also known as SORLA and LR11) encodes for the sortilin-
related receptor L (DLR class) A. The gene encodes for a protein
that belongs to the family of vacuolar protein sorting 10 (VPS10)
domain-containing receptor proteins, which is mainly found
intracellularly in the paranuclear compartment and is strongly
expressed in the central nervous system. It regulates processing of
amyloid precursor protein (APP) in AD [34], and the expression of
SORL1 is reduced in the brain of AD patients, thus being of
considerable interest for understanding of the AD pathology [35].
The gene Mannosidase a, class 2A, member 1 (MAN2A1 also
known as MANA2) encodes for a a-mannosidase-2 protein, which
is a family member of the glycosyl hydrolases in the Golgi
apparatus. A mutation in a mouse homolog of this gene has been
linked to a systemic autoimmune disease making it likely that this
gene has a relation to inflammation regulation.
PARP1 (also known as ADPRT1, PARP-1, PPOL, pADPRT-1).
This gene encodes a chromatin-associated enzyme, poly (ADP-
ribosyl) transferase-1, which modifies nuclear proteins. It is
involved in the regulation of e.g. differentiation, proliferation,
tumour transformation and the recovery of cells from DNA
damage. This enzyme may be the site of mutation in Fanconi
anaemia and may participate in the pathophysiology of type I
diabetes. It has also been suggested that PARP-1 is involved in NF-
kB driven expression of inflammatory mediators, like interleukin-1
(IL-1) [36]. An over activity of PARP-1 has been shown in the AD
brain [37]. This gene is of interest for understanding of the AD
pathology as well as inflammation.
The structure specific recognition protein-1 (SSRP1, also known
as FACT, FACT80 and T160). The encoded protein forms with
other proteins the chromatin transcriptional elongation factor
FACT, which appears to be crucial to the anticancer mechanism
of cisplatin. This protein also functions as a co-activator of the
transcriptional activator p63.
Ariadne homolog, ubiquitin-conjugating enzyme E2 binding
protein-1 (ARIH1, also known as ARI and UBCH7BP), is one of the
proteins involved in the ubiquitination process before degradation
of proteins by the 26S proteasome.
The anaphase promoting complex subunit-5 protein (ANAPC5
also known as APC5) gene encodes for the anaphase promoting
complex/cyclosome (APC/C), a large E3 ubiquitin ligase that
controls cell cycle progression by targeting a number of cell cycle
regulators such as B-type cyclins for 26S proteasome-mediated
degradation.
Gene changes in the placebo group and comparisons
with the n-3 FA group
We analyzed by t-test if genes regulated by n-3 FA
supplementation were also up-or down-regulated in the placebo
group. Only the DRG1gene were found to be significantly up
regulated in the placebo group (p=0.04; Table 1).
Table 2. Genes down-regulated by a DHA rich n-3 fatty acid or placebo supplementation.
n-3 FA group
1 Placebo group
Locus Link Genes Fold change P-value Fold change
RHOB Ras homolog gene family, member B 0.7060.26 0.0037 1.3060.79
3
VCP Valosin-containing protein 0.7260.24 0.0047 0.9460.16
4
LOC399491 LOC 399491 protein 0.7360.19 0.0032 1.0960.32
3
ZNF24 Zinc finger protein 24 0.7660.18 0.000019 0.9960.12
3
SORL1 Sortilin-related receptor L (DLR class) A 0.7760.21 0.0046 0.9560.18
MAN2A1 Mannosidase alpha, class 2A, member 1 0.7860.21 0.0029 1.0160.19
4
PARP1 Poly (ADP-ribose) polymerase family, member 1 0.8060.16 0.0024 1.0160.29
4
SSRP1 Structure specific recognition protein 1 0.8260.12 0.0022 0.9860.23
4
ARIH1 Ariadne homolog, ubiquitin-conjugating enzyme
E2 binding protein
0.8360.16 0.0027 0.8760.16
ANAPC5 Anaphase promoting complex subunit 5 0.8760.09 0.0008 1.0460.17
3
All values are means6SD.
1All genes were significantly down-regulated by the n-3 FAs treatment according to SAM based on 2000 permutations and a false discovery rate of 10%, see microarray
data analysis for details.
3Significant and
4close to significance (p=0.06–0.09) difference in fold change between the n-3 FAs and placebo groups.
doi:10.1371/journal.pone.0035425.t002
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supplementation, displayed a larger fold change in the n-3 FA
group than in the placebo group; the exception was HSD17B11
(Table 1 and 2). The difference was significant for five genes
(CD63, RHOB, LOC399491, ZNF24, ANAPC5) and close to
significance for an additional six (p=0.05–0.09) (MAN2A1, CASP4,
SUPT4H1, VCP, PARP1, SSRP1) by means of t-tests.
Individual mRNA measurements
We chose five genes for validation by RT-PCR. Out of these
five genes, two, viz. CD63 and SORL1 were significantly modulated
in accordance with changes in the microarray assay, and CASP4
was borderline significant (p=0.05) (Table 3). The inability to
confirm some genes could be due to false positive, i.e. the use of a
10% FDR, or limited power of the confirmation cohort.
Correlation analyses
When relating values for expressed genes to plasma concentra-
tions of DHA or EPA, we found that changes in DHA or EPA for
all 16 subjects correlated significantly to changes in the expression
of ANAPC5 (r=20.625; p=0.01 /Figure 3 left/, and
r=20.619; p=0.01, respectively), and RHOB (r=20.512;
p=0.04, and r=20.57; p=0.02, respectively). Thus, the more
DHA (or EPA) concentrations increased, the lower was the
expression of the ANAPC5 and RHOB genes. Moreover, we found
that changes of EPA levels, but not DHA, for all 16 subjects
correlated significantly to changes of the expression of the CASP4
gene (r=0.547; p=0.028 /Figure 3 right/). Thus, the CASP4
gene expression rose with an enhanced EPA plasma level.
Discussion
Here, we describe that 6 months of dietary supplementation of a
DHA rich fish oil formulation to elderly humans afflicted with AD
conferred significant up- or down-regulation of several genes.
They represent a wide variety of cellular functions. Notably, many
of these are associated with inflammatory reactions (viz. CD63,
HSD17B11, RAB27A, CASP4, MAN2A1 and PARP1), others with
neuroinflammatory disorders (viz. NAIP, DRG1, SORL1, CASP4
and PARP1), two processes which are highly relevant for actions of
n-3 FAs and the aim of the OmegAD study to investigate. Some of
the genes were found in both categories, emphasizing the
inflammatory component of AD process [31], [38]. Moreover,
only 1 (of 19) genes was significantly changed in the placebo
treated group. Finally, the statistically significant relation between
changes of plasma DHA and EPA levels and of the RHOB and
ANAPC5 genes is intriguing.
The four previously mentioned genome wide expression studies
in baboons, rodents and the one in healthy subjects [19], [20],
[21], [22] noted changes in 5–1000 genes in brains, livers and
PBMC, respectively, after dietary DHA or EPA rich fish oil
interventions for 3–10 weeks in rodents and 26 weeks in humans.
However and surprisingly, none of those genes coincided with
what we describe here as significantly up- or down-regulated. A
possible explanation of these inconsistencies in results might be
related to species, human populations and ages, FA types, doses,
duration as well as to target organs. Thus, our study presents
unique data on genes of relevance to long-term dietary
supplementation with a DHA-rich preparation to aged and AD-
afflicted humans.
Array techniques with a restricted set of gene probes (app. 3000
genes or less) were used in a few n-3 FA animal studies. In one, on
brain tissue, the fish oil group displayed almost the same
expression profile as the control group [11]. Another study found
an up-regulation of the transthyretin gene in the hippocampus
[12], whereas we did not in our study on human PBMC. In a third
murine study, genes encoding for IL-1a, IL-1b or NO synthase
were unaltered [13], as in our study. Two months of a DHA rich
fish oil supplementation modified 77 of 588 studied genes in
human lymphocytes [39] but, again, none was genes we identified
as up-or down-regulated.
The recently published study on healthy humans given an EPA
rich fish oil [22] (with total n-3 FA doses close to ours and for a
similar time) observed changes in more than 1000 genes, where
the magnitude of changes was often very small. The reason for the
outfall in terms of number of genes can probably be related to
using an array covering 17 000 genes, including approximately
twice as many subjects as in our study, and using a nominal p-
value 0.05 as threshold to determine significantly altered gene
expression on microarray data. The latter makes the results
difficult to compare with our analysis of microarray data with
SAM, which takes multiple comparisons into account. Since only a
fraction of all changed genes were listed in [22], we do not know if
changes were seen in the same genes as in our study. Of note, out
of 99 independent transcripts (changed by EPA) that could be
identified in [22], 16 transcripts were not represented with
probesets on our Focus array. Another 19 transcripts were
detected in less than 29 of 32 arrays, and displayed very low
signals; it has previously been demonstrated that variability in gene
expression is a function of absolute expression, i.e. a lowly
expressed gene is more variable than a highly expressed gene [40].
Results for such genes have an increased risk of being false positive
and are also more difficult to confirm in independent datasets. In
addition, some of the remaining 54 EPA-regulated transcripts in
[22] gave low signals on our Focus array. Together, these factors
can partially explain why we could not confirm the findings by
Bouwens et al [22].
Several studies have examined the effects of fish oils on
individual human genes and corresponding protein production,
documenting, inter alia, diminished ex vivo pro-inflammatory
cytokine production in mononuclear blood cells, e.g. TNF-a and
IL-1b [41], [42] and IL-6 [42] and decreased TNF-a and IL-6 in a
dose-dependent manner [43]. Fish oil also lowered gene
expression of TNF-a in renal allograft after 3 months of treatment
[44]. These findings could, however, not consistently be repeated
in other studies [45], [46]. Again, the reason for these
discrepancies may relate to n-3 FA dosage, treatment time,
whether DHA or EPA was the predominant FA (since they may
regulate genes differently) [17], [18], the cell type and the
Table 3. Individual messenger RNA measurements in the n-3
fatty acid group.
Locus Link Accession no Fold change
1 P-value
CD63 Hs00156390_m1 1.1860.25 0.02
CASP4 Hs00233437_m1 1.1760.31 0.05
4
SORL1 Hs00268342_m1 0.8460.27 0.04
RHOB Hs00269660_s1 0.8460.41 0.11
VCP Hs00200205_m1 0.9760.14 0.22
1The expression of the target gene was normalized to the LRP10 internal control
using theformula2
(Ct target calibrator – Ct target sample)/2
(Ct LRP10 calibrator – Ct LRP10 sample)
where calibrator is a random sample. Subsequently, fold change was calculated
as the ratio between values for 0 and 6 months of n-3 supplementation.
Mean6SD values (n=11).
4Near significance.
doi:10.1371/journal.pone.0035425.t003
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heterogeneous results from animal studies [11], [12], [13] where
species differences and age effects also are of significance.
As shown here, EPA as well as DHA plasma levels was
enhanced in a similar way, suggesting that DHA was converted to
EPA to some extent or that DHA was specifically cleared from
plasma. This makes it difficult to attribute gene changes to one FA.
However, DHA enriched formulas were rarely used in previous in
vivo studies.
In a previous publication from the OmegAD study [24], we
reported about changes of pro-inflammatory cytokine and growth
factor production from LPS stimulated blood mononuclear cells ex
vivo. However, we are unable to show any changes in
corresponding genes. This might be due to our gene expression
data is based on quiescent PBMCs, without LPS activation.
In vitro and after dietary supplementation, DHA increased the
sortilin-1 receptor (SORL1) mRNA and protein in murine cortical
neurons [47], but decreases have also been observed [48]. SORL1
regulates the amyloid precursor protein and this protein is also
elevated in aged DHA depleted mice [47]. In our study we found
that n-3 FA down-regulated the expression of the SORL1 gene
which is in agreement with Perez et al [48].
Our DHA enriched n-3 FAs supplementation for 6 months
caused effects with higher magnitudes on several genes compared
with placebo treatment. Moreover, the genes RHOB and ANAPC5
also showed a statistically significant correlation with the changes
of both plasma DHA and EPA levels, making them interesting
candidates for further studies on effects of n-3 FAs.
The magnitude of the gene expression changes observed here
might appear rather small, since they ranged between +72 and –
30 per cent. This is, however, what might be expected in dietary
supplementation studies in animals and humans [19], [22], [49].
In contrast, in vitro studies or in short-term animal studies larger
changes might be found. One can anticipate that acute and large
effects will vane with prolonged exposure because of an adaptation
over time.
The present study gives novel information on mechanisms for
marine lipids, suggesting that dietary n-3 FA supplementation
affected expression of genes that might influence inflammatory
processes and could be of significance for Alzheimer’s disease.
Recently, the significance of n-3 FA blood levels for telomeric
aging in patients with coronary heart disease was demonstrated
[50].
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